Study uncovers new drug target for huge class of viruses
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Apr-2026 22:16 ET (25-Apr-2026 02:16 GMT/UTC)
A University of Maryland, Baltimore County (UMBC) study, published in Nature Communications, uncovers how enteroviruses—including those causing polio, myocarditis, encephalitis, and the common cold—hijack host cell machinery to replicate. Researchers determined the structure of a cloverleaf-shaped RNA element in the viral genome bound to the viral protein 3CD, which recruits host factors to form the viral replication complex. 3CD also acts as a switch between genome copying and protein synthesis. This highly conserved mechanism across all seven enteroviruses in the study presents a stable target for developing broad-spectrum antiviral drugs that could disrupt this essential interaction and prevent replication.
Simulations of Turin, Milan and Palermo reveal that individual behaviour affects the intensity and timing of epidemics spreading in urban areas.
Scientists at the University of Granada (UGR) have revealed the real impact of human activities on endangered wildlife, taking advantage of the ‘natural experiment’ provided by the COVID lockdown. The research has been published in the journal Biological Conservation.
SARS-CoV-2 evolves rapidly, creating challenges for traditional broad antibody development strategies that rely on conserved epitopes. By surveying 7,116 published receptor-binding domain(RBD)-targeting monoclonal antibodies, we identify three single monoclonal antibodies (mAbs)—SA55, VIR-7229, and BD55-1205—and one broadly neutralizing antibodies (bsAb) Dia-19, that retain ng (in the ng/mL range) neutralization activity even when their binding footprints overlap RBD residues with mutation rates up to 39%. Notably, the three mAbs above carry ~2× more VH somatic hypermutations than the dataset median. Guided by these observations, we outline two complementary strategies: (1) an immune trajectory strategy that prioritizes higher-maturity candidates, and (2) a viral fitness-constraint strategy suited to upgrading lower-maturity antibodies. Together, these provide practical paths for discovering and improving antibodies against fast-evolving SARS-CoV-2.